NCT06769256View on ClinicalTrials.gov

Intracoronary rhTNK-tPA Versus Tirofiban in Patients With STEMI and High Thrombus Burden

PHASE4RecruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

January 1, 2025

Primary Completion Date

December 30, 2025

Study Completion Date

December 30, 2026

Conditions
ST-segment Elevation Myocardial Infarction (STEMI)
Interventions
DRUG

rhTNK-tPA, 4-8 mg

Intracoronary influsion of rhTNK-tPA (4 mg). After 10 minutes of administration, 4 mg may be given again if the thrombus burden is not significantly reduced.

DRUG

Tirofiban

Intracoronary influsion of Tirofiban (10 µg/kg) , and then administered intravenously at 0.075-0.15 µg/kg.min for 36 h or longer

Trial Locations (1)

Unknown

RECRUITING

Fuwai Central China Cardiovascular Hospital, Zhengzhou

All Listed Sponsors
lead

Henan Institute of Cardiovascular Epidemiology

OTHER